The relationship between the agonist-induced activation and desensitization of the human tachykinin NK2 receptor expressed in Xenopus oocytes.
1. Repeated applications of neurokinin A (NKA) to oocytes injected with 25 ng wild-type hNK2 receptor cRNA caused complete attenuation of second and subsequent NKA-induced responses while analogous experiments using repeated applications of GR64349 and [Nle10]NKA(4-10) resulted in no such desensitization. This behaviour has been previously attributed to the ability of the different ligands to stabilize different active conformations of the receptor that have differing susceptibilities to receptor kinases (Nemeth & Chollet. 1995). 2. However, for Xenopus oocytes injected (into the nucleus) with 10 ng wild-type hNK2 receptor cDNA, a single 100 nM concentration of any of the three ligands resulted in complete desensitization to further concentrations. 3. On the other hand, none of the ligands caused any desensitization in oocytes injected with 0.25 ng wild-type hNK2 receptor cRNA. even at concentrations up to 10 microM. 4. The two N-terminally truncated analogues of neurokinin A have a lower efficacy than NKA and it is likely that it is this property which causes the observed differences in desensitization, rather than the formation of alternative active states of the receptor. 5. The peak calcium-dependent chloride current is not a reliable measure of maximal receptor stimulation and efficacy is better measured in this system by studying agonist-induced desensitization. 6. The specific adenylyl cyclase inhibitor SQ22536 can enhance NKA and GR64349-mediated desensitization which suggests that agonist-induced desensitization involves the inhibition of adenylyl cyclase and the subsequent down-regulation of the cyclic AMP-dependent protein kinase, possibly by cross-talk to a second signalling pathway.
Department of Pharmacology, The University of Leeds.
S
S
Maudsley
J P
JP
Gent
J B
JB
Findlay
D
D
Donnelly
D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D002118:Calcium / Q000378:metabolism; D018118:Chloride Channels / Q000502:physiology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D015288:Neurokinin A / Q000031:analogs & derivatives / Q000494:pharmacology; D009865:Oocytes; D018408:Patch-Clamp Techniques; D010446:Peptide Fragments / Q000494:pharmacology; D018041:Receptors, Neurokinin-2 / Q000819:agonists* / Q000096:biosynthesis / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects; D014982:Xenopus laevis
D000067956:Adenylyl Cyclase Inhibitors; D018118:Chloride Channels; D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D018041:Receptors, Neurokinin-2; C061060:neurokinin A (4-10), Nle(10)-; C068031:neurokinin A (3-10), lysyl(3)-glycyl(8)-R-lactam-leucine(9)-; D015288:Neurokinin A; D017868:Cyclic AMP-Dependent Protein Kinases; D002118:Calcium